Online Database of Chemicals from Around the World

双异丙吡胺
[CAS# 3737-09-5]

供应商
APIChem Technology Co., Ltd. 中国 询价快递  
+86 (571) 8678-2096
sales@apichemistry.com
化学品生产商(2009 年起)
Alfa Chemistry 美国 询价快递  
+1 (201) 478-8534
inquiry@alfa-chemistry.com
化学品供销商(2012 年起)
chemBlink 标准供应商(2012 年起)
Alsachim SAS 法国 询价快递  
+33 (368) 240-080
contact@alsachim.com
化学品生产商
BOC Sciences 美国 询价快递  
+1 (631) 485-4226
info@bocsci.com
Skype 聊天
化学品供销商
chemBlink 集群供应商(2012 年起)
ChemPacific Corp 美国 询价快递  
+1 (410) 633-5771
sales@chempacific.com
化学品生产商(1995 年起)
Fluorochem Ltd. 英国 询价快递  
+44 (1457) 860-111
enquiries@fluorochem.co.uk
化学品生产商
Glentham Life Sciences 英国 询价快递  
+44 (2033) 978-798
info@glenthamls.com
化学品供销商(2013 年起)
International Laboratory Limited 美国 询价快递  
+1 (650) 278-9963
admin@intlab.org
化学品生产商(2002 年起)
Ryan Scientific, Inc. 美国 询价快递  
+1 (843)-884-4911
sales@ryansci.com
化学品生产商
Santa Cruz Biotechnology, Inc. 美国 询价快递  
+1 (831) 457-3800
scbt@scbt.com
化学品生产商
基本信息
产品分类 原料药 >> 循环系统用药 >> 抗心律失常药
产品名称 双异丙吡胺
英文名 Disopyramide Free Base
别名 4-(Diisopropylamino)-2-Phenyl-2-(2-Pyridyl)Butanamide; 4-(Diisopropylamino)-2-Phenyl-2-(2-Pyridyl)Butyramide; 4-(Di(Propan-2-Yl)Amino)-2-Phenyl-2-Pyridin-2-Yl-Butanamide
分子结构 CAS 登录号:3737-09-5, 双异丙吡胺
分子式 C21H29N3O
分子量 339.48
CAS 登录号 3737-09-5
EINECS 登录号 223-110-2
分子行输入简码 SMILES C1=CC=CC=C1C(C2=CC=CC=N2)(CCN(C(C)C)C(C)C)C(N)=O
国际化学标识码 InChI 1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
国际化学标识检索码 InChIKey UVTNFZQICZKOEM-UHFFFAOYSA-N
物理化学性质
密度 1.1±0.1g/cm3 (计算值)
沸点 505.2±50.0°C at 760 mmHg (计算值)
闪点 259.4±30.1°C (计算值)
安全数据
SDS 化学品安全技术说明书参考文本
参考文献
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Peak Time, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Time' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in hours unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Peak-Time' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (1.3), Enoxaparin (3), Epoetin Alfa (SC: 18, IP:12), Etanercept (SC-SD:72(48-96)), Filgrastim (4-5.8), Heparin (3), Interferon Alfa (IM:3.8,SC:7.3), Interferon Beta (SC:1-8), Lithium (IR:0.5-3, SR:2-6), Mycophenolate (MPA: 1.1-2.2), Prednisolone (1.5+-0.5), Sargramostim (A,SC: 1-3, C,SC:1.5-4) and Streptokinase (0.9+-0.21) have not been provided here. In all, 270 drugs and their 'Peak-Time' values are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
市场分析报告
请浏览双异丙吡胺市场分析报告总目录
相关产品
(4-氯苯基)苯基吡啶-4-基甲醇  直接黑 154  甲基三氟硅烷  2-[甲基(1-氧代十六烷基)氨基]乙烷磺酸钠  3,3'-[氧基二[(1-氧代-2,1-乙二基)亚...  3a,6,6,9a-四甲基十二氢萘并[2,1-b]...  三氟甲基硫五氟化物  5-苯基-1,2,4-恶二唑-3-羧酸甲酯  2-(二环戊基氨基)-N-(二苄基)-乙酰胺  三氟甲基次氟酸酯  2-邻甲苯基氨基-噻唑-4-酮  1-(4-溴丁氧基)-2,4-二氯苯  N-[5-[二(2-羟基乙基)氨基]-2-[(2-...  1-甲基-1H-嘧啶-2-酮  3-甲硫基-4-羟基乙酰苯胺